Introduction {#s1}
============

The regulation of immune response and controlling inflammation are the customary roles of human neutrophil cells. Along with other serine proteases, human neutrophils secrete HNE, which is a 29 kDa serine proteases of the chymotrypsin family. HNE contains a charge relay system consisting of the catalytic triad of aspartate, serine, and histidine residues that are dispersed throughout the polypeptide. Neutrophil elastase is closely related to other cytotoxic immune serine proteases, such as cathepsin G, proteinase 3, and the granzymes ([@B60]; [@B20]). It has a broad substrate specificity. For example, the intracellular HNE breaks down pathogenic proteins, whereas the extracellular HNE helps in the migration of neutrophils to the inflammation sites through the degradation of the extracellular matrix proteins. HNE has the ability to degrade the body\'s own cellular matrix as well as proteins that are foreign to the body. HNE also conducts proteolysis and plays a significant role in several biological processes. Despite the positive attributes, overproduction and uncontrolled functioning of elastase may produce devastating effects and cause serious damage to the host ([@B6]).

Under normal conditions, the activity of HNE is controlled by endogenous inhibitors including secretory leukocyte proteinase inhibitor, α1-antitrypsin (α1-AT), α2- macroglobulin, and elafin, but excessive and uncontrolled activity of HNE can cause serious damage to the tissues resulting in COPD, cyclic hematopoiesis, pulmonary emphysema (the loss of lungs elasticity), rheumatoid arthritis, pancreatitis, cystic fibrosis, psoriasis and bullous dermatoses, asthma, and systemic inflammatory response syndrome ([@B21]; [@B13]; [@B6]; [@B61]). HNE also localizes to Neutrophil extracellular traps (NETs) through its high DNA affinity, an unusual property for serine proteases. Studies have established that NETs are associated with increased lung injury and mucus clogging in cystic fibrosis ([@B60]; [@B24]). A wide variety of studies have highlighted the proteolytic activity of elastase in causing structural changes, such as higher mean linear intercept and alveolar enlargement both in mice and in rats. Several changes resulted from elastase administration such as disorganized elastin, degradation of proteoglycans, and abnormal collagen remodeling. Regarding the dose and number of elastase challenges, many scientific groups demonstrated that mice subjected to five elastase administrations with a 1-week interval between them developed not only a more severe alveolar destruction, but also systemic manifestations, such as diaphragmatic dysfunction, weight loss, pulmonary arterial hypertension, and exercise intolerance ([@B7]; [@B6]; [@B17]). Thus, inhibition of elastase by chemical drugs has also been suggested as a way to recover from different inflammatory diseases. Unfortunately, the present anti-inflammatory drugs are only alleviating the symptoms of these diseases but not the progression of the disease ([@B2]). Sivelestat is the only approved drug working as a selective HNE inhibitor. However, clinical trials revealed an insufficient therapeutic efficacy of the drug in human severe lung injury and respiratory inflammation ([@B74]). Additionally, sivelestat has the risks of organ toxicity and poor pharmacokinetics ([@B62]; [@B17]). The problem in developing new elastase inhibitors is the interference function of elastase with other proteases.

The recognition of neutrophil elastase as a promising target in chronic inflammatory diseases has increased ([@B63]; [@B9]; [@B17]). This is why we have chosen to shed light on natural polypeptides as significant inhibitors of elastases, which could be used as hit-to-lead compounds for further development. This review basically summarizes the reported natural polypeptides of different sources (bacterial, plant, fungal, and animal origin) as potential inhibitors of elastase, and lists the relevant structures and activity relationship for the high active polypeptides-based inhibitors. Additionally, this review article offers information about the chemical structures and structural features of these compounds, structural elucidation including their absolute configuration, and structure-activity relationship.

Generally, natural peptides have poor absorption, distribution, metabolism, and excretion (ADME) properties with rapid clearance, sometimes low solubility, low permeability, and a short half-life. Strategies have been developed to improve peptide drugability through prolonging half-life, reducing renal clearance and proteolysis, and enhancing permeability. *In silico*, *in vitro*, and *in vivo* tools are available to evaluate ADME characteristics of natural peptides, and structural functional modification strategies are ongoing to improve peptide developability. Clear understanding and improving the physicochemical properties that govern peptide conformation is critical in assessing the impact on potency and ADME properties (*e.g.*, stability, permeability, and PK) ([@B8]).

Porcine pancreatic elastase (PPE) has the advantage of being inexpensive and is able to induce features of lung damage and panacinar emphysema.

Anti-elastase Polypeptides of Bacterial Origin {#s2}
==============================================

Polypeptides From the Cyanobacteria *Lyngbya* spp. {#s2_1}
--------------------------------------------------

The genus *Lyngbya* (marine cyanobacteria) is a prolific producer of peptides. The depsipeptide *lyngbyastatin* 4 (**1**) ([**Figure 1**](#f1){ref-type="fig"}) is produced by the marine cyanobacterium *Lyngbya confervoides* from the Florida Atlantic coast. The planar structure of lyngbyastatin 4 (**1**) was confirmed by NMR measurements, whereas the absolute stereochemistry was corroborated through chiral HPLC analysis of its hydrolyzed moieties. Compound **1** contains an unusual aa homotyrosine and a residue of 3-amino-6-hydroxy-2-piperidone (Ahp). It selectively inhibited PPE *in vitro* with an IC~50~ = 0.03 µM ([@B36]). In another study, compound **1** potently inhibited PPE and HNE (IC~50~ 0.041 ± 2.0 and 0.049 ± 1.4 µM, respectively) ([@B53]). This compound showed no cytotoxicity to various cancerous cell lines. Lyngbyastatin 4 (**1**) is an analogue of several marine cyanobacterial compounds such as dolastatin 13, and it was revealed that many of the dolastatins are originated from cyanobacteria ([@B36]).

![Structures of lynbyastatins, somamide B, Bouillomides, and kempopeptin A from different *Lyngbya* spp. They are cyclic depsipeptides containing Ahp unit; all (except kempopeptin A) having Abu unit neighbor to the Ahp unit. The Ahp residue contains a glutamate semi-aldehyde bonded as hemi-aminal to the amide nitrogen of the following aa; kempopeptin A is a new Ahp-containing depsipeptide and possessing N-acetylated Pro. The ester linkage for these depsipeptides was formed between a threonine OH group and the hydrophobic C-terminus of the precursor peptide.](fphar-11-00688-g001){#f1}

Three more lyngbyastatins, 5-7 (**2-4**), and a cyclodepsipeptide somamide B (**5**) were discovered in the culture of cyanobacteria, *Lyngbya* spp., (South Florida). The chemical structures of compounds **2-5** ([**Figure 1**](#f1){ref-type="fig"}) were established due to NMR measurements, while the absolute configuration was established based on Marfey\'s analysis of the acid hydrolysis. All these compounds **2-5** selectively and potently inhibited PPE ([@B58]). The potent PPE inhibitory activities of compounds **2-5** were observed with similar IC~50~ values of 0.0032 (**2**), 0.0033 (**3**), 0.0083 (**4**), and 0.0095 (**5**) µM ([@B58]). In another study, compound **4** potently inhibited PPE and HNE with IC~50~ values of 0.003 and 0.0023 µM, respectively ([@B53]). Compound **4** potently and specifically inhibited elastase where it was tested at a single concentration of 10 µM against a group of 68 proteases and it showed preferential and complete inhibition for the serine proteases elastase, proteinase K, and chymotrypsin ([@B53]). As part of the mode of action of these peptides, Salvador et al. studied their selective inhibitory activity against elastase through co-crystallization of the most potent inhibitor, lyngbyastatin 7 (**4**), with PPE. The co-crystal complex of the PPE−lyngbyastatin 7 was solved at 1.55 Å resolution. The study revealed that these compounds act as substrate mimics, where the Abu moiety (2-amino-2-butenoic acid) and the N-terminal residues occupy subsites S1 to S4. Besides a non-bonded interaction of ethylidene moiety of Abu unit with Ser203, it also binds to Gly201 and Ser222 through H-bonding, and an indirect H-bond with Thr44 through a molecule of water ([@B53]). Due to the selectivity and potency of lyngbyastatin 7 (**4**) in inhibiting PPE, it was considered as a promising lead and subjected to further developmental studies ([@B32]).

Marine cyanobacteria continue to furnish polypeptides, as *Lyngbya semiplena* (Tumon Bay, Guam) provided three cyclodepsipeptides, lyngbyastatins 8-10 (**6-8**) ([**Figure 1**](#f1){ref-type="fig"}). These isolates were characterized by MS, ESIMS fragmentation, NMR, and chemical decomposition, and were found to have similar structural features to lyngbyastatin 4 (**1**). Compounds **6-8** inhibited PPE with IC~50~ 0.123, 0.21, and 0.12 µM, respectively ([@B27]). Structure-activity relationship of compounds **6-8** was compared to that of lyngbyastatin 7 (**4**), and it was proposed that differences in structure of the side chain contributed to their potency reduction. In addition, the occurrence of hydrophobic moieties in the pendant chain is supposed to establish electrostatic and H-bonding interactions with the enzyme. However, the presence of a bromide atom didn\`t significantly impact the activity of **8** compared to those of **6** and **7** ([@B27]).

The two depsipeptide analogues of dolastatin 13, bouillomides A (**9**) and B (**10**) ([**Figure 1**](#f1){ref-type="fig"}), were characterized and found in the extract of the cyanobacterium *Lyngbya bouillonii*. Both compounds selectively inhibited PPE with the same IC~50~ value of 1.9 µM ([@B50]). [@B59] identified a cyclodepsipeptide named kempopeptin A (**11**) ([**Figure 1**](#f1){ref-type="fig"}) which was isolated from *Lyngbya* spp. This compound exhibited an IC~50~ against PPE of 0.3 μM. Peptide **11** selectively inhibited elastase activity by binding through the aa residue between Ahp and Thr ([@B59]).

As a conclusion, in compounds **1**-**11**, a 6-unit cyclic core, having Ahp and a pendant side chain, is very rigid, due to H bonding between Ahp and Val, which makes the hydrolysis of the inhibitor difficult. The Abu moiety adjacent to the Ahp unit makes the elastase more susceptible to the lyngbyastatin series ([@B27]) due to H-bonding.

*Lyngbya confervoides* (southeastern Florida) produced more cyclodepsipeptides, tiglicamides A-C (**12-14**), and largamides A-C (**15-17**) ([**Figure 2**](#f2){ref-type="fig"}). The unique feature of these compounds is that they contain an unusual moiety, viz. tiglic acid. Compounds **12-14** moderately inhibited PPE *in vitro* with IC~50~ between 2.1 and 7.3 µM ([@B38]). Authors further reported 2-3 times lower activity, against PPE or other mammalian elastases, of compounds **12-14** as compared to lyngbyastatins 5-7 (**2-4**) ([@B36]; [@B58]). The investigators also identified the corresponding largamide methyl esters of compounds **12--14**, which were supposed to be the isolation artifacts, however, these ester derivatives helped to establish SAR, and it was proposed that carboxylic acid moiety is not responsible for the activity of elastase inhibition, since methylation at that position did not affect the activity ([@B38]). The largamides A-C (**15-17**) also have medium inhibition of PPE activity *in vitro* with IC~50~ between 0.5 and 1.4 μM but no activity against chymotrypsin and trypsin up to 50 μM. It was suggested that the carboxylic acid functionality of the glutamic acid moiety in largamides A-C (**15-17**) play a role in elastase inhibition. They showed moderate *in vitro* activity against PPE in a dose-dependent manner with IC~50~ 1.4, 0.5, and 1.2 μM, respectively but remain inactive against the tested cancerous cell lines IMR-32, HT29, and U2OS ([@B37]).

![Structures of tiglicamides A-C (**12**-**14**) and largamides A-C (**15**-**17**) from *Lyngbya confervoides*, all are cyclic depsipeptides with unusual tiglic acid and Abu moieties and without Ahp unit.](fphar-11-00688-g002){#f2}

Polypeptides From the Cyanobacterium *Symploca* sp. {#s2_2}
---------------------------------------------------

Salvador et al. isolated the symplostatins 5-10 (**18-23**) ([**Figure 3**](#f3){ref-type="fig"}) from the red cyanobacterium *Symploca* sp. (Cetti Bay, Guam). Compounds **21**-**23** potently inhibited PPE with IC~50~ values 0.043, 0.037, and 0.044 µM, respectively, and also potently inhibited HNE with IC~50~ values of 0.041, 0.028, and 0.021 µM, respectively, and compounds **18**-**20** gave higher IC~50~ values from 0.121 to 0.195 µM. Through SAR study and X-ray co-crystal structural analyses, it was analyzed that compounds **21-23**, containing N-Me-Tyr, have a higher potential than the N-Me-Phe analogues **18-20** in elastase inhibition. It is further observed that Ile to Val substitution and pendant side chain have no effect on the activity. Compounds **21-23** and lyngbyastatins 4 (**1**) and 7 (**4**) exhibited more potential in inhibiting the PPE than the standard drug sivelestat, whereas compounds **18-20** exhibited higher IC~50~ values comparable to the activity of sivelestat ([@B53]).

![Structures of symplostatins 5-10 (**18**-**23**) isolated from cyanobacterium *Symploca* sp. and sivelestat. They comprise a 19-membered ring containing one lactone, 5 lactam links, and having Ahp and Abu units.](fphar-11-00688-g003){#f3}

To study the cytoprotective effects of **18** against elastase-induced antiproliferation and apoptosis, investigators utilized the BEAS-2B (bronchial epithelial cell line), an SV-40. Compound **18** prevented the antiproliferative effect of elastase on MTT assayagainst BEAS-2B cell with an IC~50~ 0.077 µM at 24 h ([@B53]). A striking feature of compound **18** is that it showed a comparable potential to sivelestat and didn\`t show any toxicity on the bronchial cells. In conclusion, it was stated that symplostatin 5 (**18**) alleviated chronic pulmonary diseases. Therefore, compound **18** offers a remarkable window to establish the molecular basis and biomarkers for elastase inhibitors that can aid in the creation of second generation inhibitors ([@B53]).

Polypeptide From the Cyanobacterium *Stigonema* sp. {#s2_3}
---------------------------------------------------

Another depsipeptide, stigonemapeptin (**24**) ([**Figure 4**](#f4){ref-type="fig"}), was produced by *Stigonema* sp. (a freshwater cyanobacterium from northern Wisconsin). The characteristic feature of **24** was that it contains an Ahp residue and the modified aa Abu and N-formylated proline residue. Compound **24** showed *in vitro* PPE inhibition with IC~50~ 0.3 μM ([@B23]).

![Structure of stigonemapeptin (**24**) isolated from the freshwater cyanobacterium *Stigonema* sp. (northern Wisconsin).](fphar-11-00688-g004){#f4}

Polypeptides From the Cyanobacteria *Oscillatoria* spp. {#s2_4}
-------------------------------------------------------

The cyclic depsipeptide oscillapeptin (**25**) ([**Figure 5**](#f5){ref-type="fig"}) was obtained from another cyanobacterium, *Oscillatoria agardhii* (NIES-204). Compound **25** inhibited elastase enzyme activity with IC~50~ 2.5 µM. This depsipeptide **25** contains Ahp, an acyl group, and 7 aa or their derivatives and hence it is related to dolastatin 13 and micropeptins. The unusual feature of oscillapeptin (**25**) is that it has two homotyrosine units and N,O-dimethyltyrosine moiety, which is rare in natural peptides. This unique feature of similar peptides with a variety of aa compositions offers interest to biochemists to study their biosynthetic pathway ([@B54]). During other investigations, *Oscillatoria agardhii* in three different cultured conditions produced oscillapeptins A, B, D, and E (**26-29**) ([**Figure 5**](#f5){ref-type="fig"}). These compounds inhibited elastase with IC~50~ 2.5, 4.2, 2.6, and 2.7 µM, respectively ([@B22]).

![Structures of scyptolins A and B (**58--59**); they hold a 19-membered ring containing one lactone (involving the side chain hydroxyl of a threonine residue), an Ahp residue and 5 lactam links.](fphar-11-00688-g005){#f5}

The cyclic depsipeptides oscillapeptin G (**30**) and oscillapeptilides 97-A (**31**) and -B (**32**) ([**Figure 5**](#f5){ref-type="fig"}) were produced by the toxic strains of *Oscillatoria agardhii*, having the elastase inhibition property with IC~50~ 1.0, 6.9, and 3.9 µM, respectively ([@B16]). The tricyclic peptide microviridin I (**33**) ([**Figure 6**](#f6){ref-type="fig"}) was obtained from the non-toxic strain of *Oscillatoria agardhii*. This compound showed inhibitory activity towards elastase release with IC~50~ 1.9 µM ([@B16]).

![Structures of microviridins I, G, and H.](fphar-11-00688-g006){#f6}

Polypeptides From the Cyanobacteria *Nostoc* spp. {#s2_5}
-------------------------------------------------

Another cyanobacterium, *Nostoc minutum* (NIES-26), inhabiting fresh water, has been reported to produce microviridin-type peptides, which were identified as microviridins G (**34**) and H (**35**) ([**Figure 6**](#f6){ref-type="fig"}). Both compounds potently inhibited elastase activity with IC~50~ 1.0 and 1.7 µM, respectively ([@B42]). Although investigators did not comment on the structural features and level of activity of **34** and **35**, this may be because both the compounds are highly active, however, **34** is more active than **35** which could be attributed to additional cyclization in the form of lactone in compound **34**, that results in slightly increased hydrophobicity.

Nostopeptins A (**36**) and B (**37**) ([**Figure 7**](#f7){ref-type="fig"}) were produced by the cyanobacterium *Nostoc Minutum* (NIES-26). These compounds were characterized as cyclic depsipeptides-containing Ahp but not Abu unit. Both the compounds inhibited elastase with IC~50~ 1.3 and 1.2 µM, respectively ([@B46]).

![Structures of nostopeptins A and B.](fphar-11-00688-g007){#f7}

From the cyanobacterium *Nostoc insulare* (Nostocales), eight new cyanopeptolins named insulapeptolides A--H (**38-45**) ([**Figure 8**](#f8){ref-type="fig"}) were isolated guided by their bioactivity toward the target enzyme HLE, MALDITOF, and molecular biological analysis. The insulapeptolides A--H (**38-45**) selectively inhibited HLE with IC~50~ 0.1, 0.1, 0.09, 0.08, 3.2, 1.6, 3.5, and 2.7 µM, respectively ([@B41]).

![Structures of insulapeptolides A--H (**38**-**45**), all having Ahp unit but not Abu unit. These depsipeptides contain a 19-membered ring created from six aa residues by the formation of lactone between a side chain OH group of the first residue and the C-terminal carboxylate.](fphar-11-00688-g008){#f8}

Polypeptides From the Cyanobacteria *Microcystis* spp. {#s2_6}
------------------------------------------------------

The new microviridins B (**46**) and C (**47**) ([**Figure 9**](#f9){ref-type="fig"}) were also obtained from *Microcystis aeruginosa*. These compounds potentially inhibited elastase activity with IC~50~ 2.6 and 4.8 µM, respectively ([@B45]).

![Structures of microviridins B and C isolated from *Microcystis aeruginosa*.](fphar-11-00688-g009){#f9}

The aqueous extract of *Microcystis* sp. produced several polypeptides including micropeptins MM836 (**48**), MM932 (**49**), MM978 (**50**), anabaenopeptins MM823 (**51**), and MM850 (**52**) ([**Figure 10**](#f10){ref-type="fig"}). These metabolites were purified using sephadex LH-20 and RP-ODS column. These compounds inhibited the elastase activity with IC~50~ between 4.4 and 50.0 µM, with compound **49** displaying the most potential (IC~50~ = 4.4 µM) ([@B73]) ([**Table 1**](#T1){ref-type="table"}). No Data is available on either mode of action or the cytotoxicity of compounds **48**-**52**. However, comparison of the IC~50~ values disclosed that the degree of binding of the micropeptins to the elastase catalytic pocket increases when residue-2 is comprised of tyrosine instead of phenylalanine. Anabaenopeptins are mild inhibitors of serine proteases as compared to the micropeptins, however, among anabaenopeptins, the higher binding affinity of **52** is attributed to an OMeArg in the ureido-bridge of **52**, which is OMeGlu in **51**.

![Structures of micropeptins **48-50** are with Ahp unit, **53**-**56** are also with Ahp unit, and the anabaenopeptins **51-52** are without Ahp unit. These micropeptins are depsipeptides. The anabaenopeptins are hexapeptides and cyclic through the cyclization of the C-terminal aa carboxyl to the ƹ-amine residue of the N-terminal-D-lysine, while the α-amine of this lysine fraction is linked through an ureido-bridge to the side chain of another aa. All anabaenopeptins described to date from cyanobacteria, contain D-lysine, and have an L-absolute configuration for the other aa.](fphar-11-00688-g010){#f10}

###### 

Natural polypeptides having activity against elastase and their IC~50s~.

                                                   Compound                Name                   IC~50~ against HNE/µM   IC~50~ against PPE/µM   Reference
  ------------------------------------------------ ----------------------- ---------------------- ----------------------- ----------------------- ------------------
  Anti-elastase polypeptides of bacterial origin   **1**                   Lyngbyastatin 4        0.049                   0.03                    ([@B36]; [@B53])
  In another study, 0.04                                                                                                                          
  **2**                                            Lyngbyastatin 5                                0.0032                  ([@B58]; [@B53])        
  **3**                                            Lyngbyastatin 6                                0.0033                  ([@B58]; [@B53])        
  **4**                                            Lyngbyastatin 7         0.0023                 0.0083                  ([@B58]; [@B53])        
  In another study, 0.003                                                                                                                         
  **5**                                            Somamide B              0.0095                 0.0095                  ([@B58]; [@B53])        
  **6**                                            Lyngbyastatin 8                                0.123                   ([@B27])                
  **7**                                            Lyngbyastatin 9                                0.210                   ([@B27])                
  **8**                                            Lyngbyastatin 10                               0.120                   ([@B27])                
  **9**                                            Bouillomide A                                  1.9                     ([@B50])                
  **10**                                           Bouillomide B                                  1.9                     ([@B50])                
  **11**                                           Kempopeptin A                                  0.3                     ([@B59])                
  **12**                                           Tiglicamide A                                  2.1                     ([@B38])                
  **13**                                           Tiglicamide B                                  6.9                     ([@B38])                
  **14**                                           Tiglicamide C                                  7.3                     ([@B38])                
  **15**                                           Largamide A                                    1.4                     ([@B37])                
  **16**                                           Largamide B                                    0.5                     ([@B37])                
  **17**                                           Largamide C                                    1.2                     ([@B37])                
  **18**                                           Symplostatin 5                                 0.068                   ([@B53])                
  **19**                                           Symplostatin 6                                 0.089                   ([@B53])                
  **20**                                           Symplostatin 7                                 0.077                   ([@B53])                
  **21**                                           Symplostatin 8          0.041                  0.043                   ([@B53])                
  **22**                                           Symplostatin 9          0.028                  0.037                   ([@B53])                
  **23**                                           Symplostatin 10         0.021                  0.044                   ([@B53])                
  **24**                                           Stigonemapeptin                                0.3                     ([@B23])                
  **25**                                           Oscillapeptin                                  2.5                     ([@B54])                
  **26**                                           Oscillapeptin A                                2.5                     ([@B22])                
  **27**                                           Oscillapeptin B                                4.2                     ([@B22])                
  **28**                                           Oscillapeptin D                                2.6                     ([@B22])                
  **29**                                           Oscillapeptin E                                2.7                     ([@B22])                
  **30**                                           Oscillapeptin G                                1.0                     ([@B16])                
  **31**                                           Oscillapeptilide 97-A                          6.9                     ([@B16])                
  **32**                                           Oscillapeptilide 97-B                          3.9                     ([@B16])                
  **33**                                           Microviridin I                                 1.9                     ([@B16])                
  **34**                                           Microviridin G                                 1.0                     ([@B42])                
  **35**                                           Microviridin H                                 1.7                     ([@B42])                
  **36**                                           Nostopeptin A                                  1.3                     ([@B46])                
  **37**                                           Nostopeptin B           1.2                                            ([@B46])                
  **38**                                           Insulapeptolide A       0.1                                            ([@B41])                
  **39**                                           Insulapeptolide B       0.1                                            ([@B41])                
  **40**                                           Insulapeptolide C       0.09                                           ([@B41])                
  **41**                                           Insulapeptolide D       0.08                                           ([@B41])                
  **42**                                           Insulapeptolide E       3.2                                            ([@B41])                
  **43**                                           Insulapeptolide F       1.6                                            ([@B41])                
  **44**                                           Insulapeptolide G       3.5                                            ([@B41])                
  **45**                                           Insulapeptolide H       2.7                                            ([@B41])                
  **46**                                           Microviridin C                                 2.6                     ([@B45])                
  **47**                                           Microviridin C                                 4.8                     ([@B45])                
  **48**                                           Micropeptin MM836                              45.5                    ([@B73])                
  **49**                                           Micropeptin MM932                              4.4                     ([@B73])                
  **50**                                           Micropeptin MM978                              19.1                    ([@B73])                
  **51**                                           Anabaenopeptin MM823                           50.5                    ([@B73])                
  **52**                                           anabaenopeptin MM850                           14.3                    ([@B73])                
  **53**                                           Micropeptin HH978                              17.6                    ([@B30])                
  **54**                                           Micropeptin HH960                              55.5                    ([@B30])                
  **55**                                           Micropeptin HH992                              16.9                    ([@B30])                
  **56**                                           micropeptin DR1006                             13.0                    ([@B1])                 
  **57**                                           Molassamide                                    0.03                    ([@B19])                
  **58**                                           Scyptolin A                                    1.6                     ([@B33]; [@B34])        
  **59**                                           Scyptolin B                                    1.4                     ([@B33]; [@B34])        
  **60**                                           planktopeptin BL1125                           0.096                   ([@B18])                
  **61**                                           planktopeptin BL843                            1.7                     ([@B18])                
  **62**                                           planktopeptin BL1061                           0.040                   ([@B18])                
  **63**                                           brunsvicamide A         3.1                                            ([@B55])                
  **64**                                           Brunsvicamide B         2.0                                            ([@B55])                
  **65**                                           Brunsvicamide C         4.4                                            ([@B55])                
  **66**                                           FR901277                0.2                    0.3                     ([@B44])                
  **67**                                           FR134043                0.04                                           ([@B43])                
  **68**                                           YM-47141                1.5                                            ([@B47]; [@B71])        
  **69**                                           YM-47142                3.0                                            ([@B47]; [@B71])        
  Anti-elastase polypeptide of plant origin        **70**                  Ixorapeptide II                                5.6                     ([@B28])
  Anti-elastase polypeptides of fungal origin      **71**                  Desmethylisaridin C2   10.0                                            ([@B5])
  **72**                                           Isaridin E              12.7                                           ([@B5])                 
  **73**                                           Isaridin C2             12.1                                           ([@B5])                 
  **74**                                           Roseocardin             15.1                                           ([@B5])                 

*Microcystis aeruginosa* (IL-399) synthesized micropeptins HH978 (**53**), HH960 (**54**), and HH992 (**55**) ([**Figure 10**](#f10){ref-type="fig"}). Compounds **53-55** inhibited elastase with IC~50~ 17.6, 55.5, and 16.9 μM, respectively, but not thrombin and trypsin at a concentration of 45.5 μM, which showed their selectivity towards elastase enzyme. Comparison of the elastase inhibitory potential of **53** and **54** revealed the importance of the Ahp-6-OH group. However, in contrast, the comparison of the anti-elastase potential of compounds **53** and **55** revealed that the enzyme is liberal to the structural variation and also accepts the Mpc moiety ([@B30]). Another micropeptin, DR1006 (**56**) ([**Figure 10**](#f10){ref-type="fig"}), has also been reported as a metabolite of *Microcystis aeruginosa* and inhibited elastase with an IC~50~ 13.0 µM ([@B1]). The SAR studies with other co-isolated compounds concluded that the elastase inhibitory activity of compound **56** can be attributed to the leucine moiety in the 5^th^ position from the C-terminus. This conclusion is also consistent with the activity of other similar compounds ([@B1]).

Polypeptide From the Cyanobacterium *Dichothrix utahensis* {#s2_7}
----------------------------------------------------------

Molassamide (**57**) ([**Figure 11**](#f11){ref-type="fig"}), an analogue of dolastatin, is considered to be the first peptide separated from marine cyanobacterial assemblages of *Dichothrix utahensis* (from Brewer\'s Bay, Virgin Islands and from the Molasses Reef, Florida). The structure of **57** was established through NMR spectroscopic techniques, while the absolute configuration at chiral centers was assigned through chiral HPLC analysis of the hydrolyzed products. Compound **57** exhibited potent protease-inhibition activity, with IC~50~ 0.03 and 0.23 µM against PPE and chymotrypsin, respectively ([@B19]).

![Structure of molassamide (**57**) has both Ahp and Abu units.](fphar-11-00688-g011){#f11}

Polypeptides From the Cyanobacterium *Scytonema hofmanni* {#s2_8}
---------------------------------------------------------

Another two cyclic depsipeptides, scyptolins A (**58**) and B (**59**) ([**Figure 12**](#f12){ref-type="fig"}), were produced by *Scytonema hofmanni* PCC 7110. Spectroscopic based analysis of their structures revealed that these metabolites have a unique side chain and an uncommon moiety 3′-chloro-*N*-methyl-Tyr. Compounds **58** and **59** consisted of the N-acylated peptide But^1^-Ala^2^-Thr^3^-Thr^4^-Leu^5^-Ahp^6^-Thr^7^-cmTyr^8^-Val^9^, to build a 19-membered ring through esterifying the Val^9^ COOH with the Thr^4^ OH. It is further explained that OH of the Thr^3^ residue in compound **59** has another esterification bond with the N-butyroyl-Ala. Both the compounds **58** and **59** are reported to possess selective inhibition of PPE *in vitro* with IC~50~ 1.6 and 1.4 µM, respectively ([@B33]; [@B34]). The crystal structure of scyptolin A-PPE demonstrated that the elastase inhibitor occupies the prominent subsites S1 through S4 of the enzyme, and this rigid structure banned hydrolysis of the complex ([@B35]). The above studies suggest that the type of aa present in between Thr and Ahp define the selective inhibition of serine proteases, which is attributed to the preferences of the different binding to specific pockets of the enzyme ([@B35]). The scyptolins\` selectivity of elastase is likely regulated by the moiety in position 5, which corresponds to the P1 position of a substrate, which is leucine in the scyptolins ([@B39]).

![Scyptolins A and B (**58**-**59**) hold a 19-membered ring containing one lactone (involving the side chain hydroxyl of a threonine residue), an Ahp residue and 5 lactam links.](fphar-11-00688-g012){#f12}

Polypeptides From the Cyanobacterium *Planktothrix rubescens* {#s2_9}
-------------------------------------------------------------

Three planktopeptins, BL1125 (**60**), BL843 (**61**), and BL1061 (**62**) ([**Figure 13**](#f13){ref-type="fig"}), were separated from the cyanobacterium *Planktothrix rubescens*. The three compounds **60-62** inhibited the activity of elastase enzyme with IC~50~ 0.096, 1.7, and 0.040 µM, respectively. It is stated that the flexible side chain moiety of compounds **60** and **62** is the factor for selectivity of elastase enzyme when compared with the activity for other enzymes ([@B18]).

![Structures of planktopeptins BL1125 (**60**), BL843 (**61**), and BL1061 (**62**) separated from *Planktothrix rubescens*.](fphar-11-00688-g013){#f13}

Polypeptides of the Cyanobacterium *Tychonema* sp. {#s2_10}
--------------------------------------------------

The brunsvicamides A-C (**63**-**65**) ([**Figure 14**](#f14){ref-type="fig"}) obtained from the cyanobacterium *Tychonema* sp. were found to comprise six aa: five aa constitute a 19-membered ring skeleton, while the sixth aa is attached through urea moiety to the α-amino moiety of the D-Lys. These compounds have a structural similarity to those of anabaenopeptins, which have a D-Lys-urea moiety linked to a terminal aa and an N-methylated peptide bond in common, which differ in their aa sequence. Compounds **63**-**65** exhibit high selectivity for HLE inhibition with Ki 1.1, 0.70, and 1.6 µM, respectively, and having IC~50~ 3.1, 2.0, and 4.4 µM, respectively. The mode of action of these compounds has been investigated through modeling with the most active metabolite, brunsvicamide B (**64**). A reference co-crystal structure of scyptolin A and PPE was used, since the cyclic peptide core of scyptolin A has exactly the same number of aa and atoms as brunsvicamides. Based on the structural similarity, the investigators studied if the cyclic core of scyptolin A mimics the brunsvicamides A-C. Thus, the computational modeling suggested that brunsvicamides A--C might act by an inhibition mechanism which is similar to scyptolin A. The crystallographic data of the complex structure scyptolin A-- elastase revealed that the active site of elastase was occupied by the macrocycle of scyptolin A in such a way as to prevent the access of water to make the cleavage difficult ([@B55]).

![Structures of brunsvicamides A-C (**63**-**65**) obtained from *Tychonema* sp.](fphar-11-00688-g014){#f14}

Polypeptides of the Bacterium *Streptomyces resistomicificus* {#s2_11}
-------------------------------------------------------------

FR901277 (**66**) ([**Figure 15**](#f15){ref-type="fig"}), a novel and unique bicyclic macrocyclic natural polypeptide, obtained from the bacterium filtrate *Streptomyces resistomicificus*, is a potent inhibitor of both PPE and HLE. Its unique bicyclic structure comprises of four normal aa \[L-Orn(1), L-Thr(2), L-Phe(5), and L-Val(7)\] and three unusual aa \[dehydroxyThr(3), AA(4), and AA(6)\], with a N-terminal of isopropyl carbonyl ([@B44]). FR901277 (**66**) inhibited both HLE and PPE with IC~50~ of 0.2 and 0.3 µM, respectively ([@B44]). FR134043 (**67**) ([**Figure 15**](#f15){ref-type="fig"}) is a disulfonated semisynthetic derivative of **66**, which also has potent inhibitory activity against HLE with IC~50~ = 0.04 µM ([@B43]).

![Structures of FR901277 (**66**), FR134043 (**67**), YM-47141 (**68**), YM-47142 (**69**); structure of the peptide ixorapeptide II (**70**) of *Ixora coccinea* (Rubiaceae), and structures of desmethylisaridin C2 (**71**), isaridin E (**72**), isaridin C2 (**73**), and roseocardin (**74**).](fphar-11-00688-g015){#f15}

Polypeptides of the Bacterium *Flexibacter* sp. Q17897 {#s2_12}
------------------------------------------------------

The two cyclic-depsipeptides, designated YM-47141 (**68**) and YM-47142 (**69**) ([**Figure 15**](#f15){ref-type="fig"}), were isolated from the fermented bacterium *Flexibacter* sp. Q17897. Both peptides are considered as the first natural compounds containing vicinal tricarbonyl functionality. They showed potent HLE inhibition with IC~50~ values of 1.5 µM and 3.0 µM, respectively ([@B47]; [@B71]). Their total synthesis has also been reported ([@B66]; [@B67]).

Anti-elastase Polypeptide of Plant Origin {#s3}
=========================================

The peptide ixorapeptide II (**70**) ([**Figure 15**](#f15){ref-type="fig"}) was discovered in the MeOH extract of *Ixora coccinea* (Rubiaceae). Compound **70** has been identified as a promising anti-inflammatory agent because it inhibited elastase release with IC~50~ value 5.6 µM. The important feature is that compound **70** exhibited a 73-fold more potent inhibition of elastase release than the commercial drug phenylmethylsulfonyl fluoride (PMSF). It was, therefore, concluded that peptide **70** could be a promising anti-inflammatory drug lead with no cytotoxicity, and may be subjected to *in vivo* studies and clinical trials ([@B28]).

Anti-elastase Polypeptides of Fungal Origin {#s4}
===========================================

Besides cyanobacterial sources, epigenetic tools have also been utilized to get elastase inhibitor peptides from fungi. For example, supplementation of suberoylanilide hydroxamic acid (SAHA) to the medium of the fungus *Beauveria felina* resulted in the isolation of the cyclodepsipeptides of the isaridin type: desmethylisaridin C2 (**71**), isaridin E (**72**), isaridin C2 (**73**), and roseocardin (**74**) ([**Figure 15**](#f15){ref-type="fig"}). Their structural elucidation was proven through extensive spectroscopic measurements and chemical derivatization and compared with the literature data, however, the sequence of the amino acids were established due to EIMS experiments. Compounds **71**-**74** inhibited FMLP-induced elastase release in human neutrophils with IC~50~ between 10.0 and 12.0 μM. SAR studies showed that the existence of allylic moiety in the co-isolated compounds destruxin A, resetoxin B, resulted in a decrease in anti-inflammatory activity. **71**-**74** exhibited anti-inflammatory activity without toxicity toward human neutrophils which were confirmed by the results of the measurement of cell viability by LDH which showed that these compounds hadn\`t increased LDH release compared to the control ([@B5]).

The peptides AFUEI and AFLEI were isolated from *Aspergillus fumigatus* and *A*. *flavus*, respectively. They have an identical aa sequence. AFUEI is composed of 68 aa residues, and it was predicted as a signal peptide. AFUEI has a promising elastase inhibition which is more potent than the other elastase inhibitors in clinical trials ([@B51]).

Anti-elastase Polypeptides of Animal Origin {#s5}
===========================================

Serine protease inhibitors (serpins) constitute a large protein class of native serine protease inhibitors with members spread over prokaryotes and eukaryotes ([@B75]). Serpins have also been found in the venom of snakes, spiders, scorpions, cone snails, cnidarians, hymenopterans, and platypuses ([@B72]). These inhibitors are mostly Kunitz-type toxins (the motif of the Kunitz-type toxins usually has a peptide chain of around 60 aa residues and is stabilized by three disulphide bridges ([@B72])). However, extensive transcriptomic and proteomic analysis of the venoms of animals also led to the discovery of non-Kunitz inhibitors ([@B69]; [@B29]). In addition, other polypeptides as elastase inhibitors have also been found in other animal sources. For example, elafin (skin-derived antileukoproteinase) was obtained from the horny layers of the human skin of patients with psoriasis where their skin was characterized by hyperproliferatin keratinocytes, and an inflammatory infiltrate consisting partly of neutrophils migrating into the affected skin epidermis. Elafin potently inhibited HLE and PPE in a 1:1 molar ratio with equilibrium dissociation constants (*Ki*) of 6 x 10^-10^ and 1 x 10^-9^ M, respectively. The aa sequencing revealed that elafin consists of 57 aa. Elafin was reported to have a crucial role in preventing elastase-mediated tissue proteolysis, which was attributed to the high affinity and the apparent specificity for elastases ([@B68]).

The elastasin peptide, identified in goats, is a serpin related to human α1-anti-chymotrypsin. Elastasin was an inhibitor of neutrophil elastase (k~ass.~ = 1.5 x 10^6^ M^-1^.S^-1^). The specific activity, resistance to oxidative and proteolytic inactivation, and the presence of a P1 leucine residue in elastasin, is unique among inhibitory serpins. This serpin seems to be the major elastase inhibitor in goat plasma, which is involved in the control of goat neutrophil elastase ([@B48]).

Pnserpin, a putative serpin from the thermophile *Pyrobaculum neutrophilum*, irreversibly inhibited elastase-like protease in a temperature range between 20 and 100°C and the inhibitory activity of pnserpin increased with the temperature ([@B75]).

AvKTI, comprising of 170 aa, is the first spider (*Araneus ventricosus*) serine protease inhibitor of Kunitz-type, obtained from the body of the spider instead of its venom. Out of 170 aa, 19-aa comprise a signal peptide, 94-aa make pro-peptide, and a Kunitz domain consisting of 57-aa peptide that shows features matching to Kunitz-type inhibitors, including a P1 lysine site and six conserved cysteine residues; it inhibited HNE IC~50~: 0.447 µM ([@B65]).

AvCI is a spider (*Araneus ventricosus*) polypeptide, consisted of 86 aa, including a 16-aa signal peptide and a 70-aa mature peptide that displays a P1 lysine residue and eight conserved cysteine residues. AvCI potently inhibited HNE with IC~50~ of 0.011 µM which was 1.65-fold more than its PPE inhibition (IC~50~ = 0.019 µM) ([@B64]).

Kim et al. reported the first bee-derived serine protease inhibitor, AcCI, which was obtained from the body and venom of Asiatic honeybee (*Apis cerana*) worker bees. AcCI was found to consist of 85-aa that includes a 20-aa signal peptide and a 65-aa mature peptide that displays a P1 site and ten cysteine residues. AcCI inhibited HNE (IC~50~: 0.038 µM) which was a 1.8-fold stronger inhibition than that against PPE (IC~50~: 0.07 µM) ([@B25]).

BmKPI is the *Buthus martensi* Kunitz-type protease inhibitor which was present in the venom gland of the scorpion *B. martensi*.It has a unique disulfide framework where it has a unique cysteine skeleton reticulated by four disulfide bridges (three disulfide bridges in many other Kunitztype proteins). The functionally expressed recombinant BmKPI peptide showed potent inhibition activity against PPE (*Ki* 1.6 x 10^-7^ M) and it is the first functionally characterized Kunitz-type elastase inhibitor derived from scorpion venom. The unique disulfide bridge Cys53--Cys61 had little effect on its elastase inhibition as shown by cysteine mutagenesis experiment ([@B4]).

Bungaruskunin is a novel serine protease inhibitor and was isolated from the venom of *Bungarus fasciatus*. The predicted precursor is composed of 83 aa residues and it has a moderate inhibitory activity against elastase (*Ki* of 6.9 x 10^-4^ M) ([@B31]).

Discussion {#s6}
==========

Inhibition of elastase enzyme is an important strategy for the alleviation of different inflammatory ailments and the discovery of new elastase modulators is deemed to be significant for the development of potential therapeutics and pharmacological tools. Polypeptides are an important class of natural products, identified as potential inhibitors of elastase enzyme, and hence can be used as a scaffold for designing more selective and potent inhibitors of the enzyme. Marine organisms are increasingly a prolific source of bioactive and unusual structural compounds ([@B10]; [@B12]; [@B11]; [@B14]; [@B15]) and the cyanobacteria of marine origin have been recognized as a fruitful arsenal of polypeptides possessing promising inhibitory activity against serine proteases. Several cyclic peptides and depsipeptides have recently been isolated from cyanobacteria, and they have an attractive molecular architecture with a constrained conformation.

Nearly all the aforementioned polypeptides are cyclic depsi-peptides containing modified and unusual aa residues, such as the modified glutamic acid moiety, Ahp (3-amino-6-OH-2-piperidone). The Ahp-containing depsipeptides have the ability to inhibit serine proteases (such as elastase, chymotrypsin, and trypsin with different inhibition selectivity depending on the differences in their aa composition), and hence their ecological role is supposed to be as inhibitors of digestive enzymes and a chemical defense against crustacean predators. They exhibited significant anti-elastase activities even up to a nanomolar concentration, specially lyngbyastatin 4 (**1**) and its analogues such as lyngbyastatins 5-7 (**2-4**) and insulapeptolides C and D (**37**, **38**).

The Ahp-bearing cyclic depsi-peptides are a significant family, primarily due to their structural diversity, predominance, and potent protease-inhibitor activity. The role of such compounds in nature may be as digestive inhibitors in herbivores, feeding deterrents, and possibly regulators of the biosynthesis of coexisting secondary constituents ([@B53]). Further SAR analysis of compounds **2-5** revealed that the Abu moiety plays a significant role in selective inhibition of elastase, and overall the cyclic structural core for **1-5** demonstrated a potent inhibitor prototype. The crystal structural data of the Abu-containing bicyclic inhibitor FR901277 (**66**) bound to PPE ([@B44]) established that the ethylidene functionality of Abu was stabilized by CH/π interaction ([@B53]). It is therefore proposed that such an enzyme-inhibitor interaction may also exist in the case of monocyclic inhibitors **1-5**. The complexity and molecular diversity of polypeptides are evident from the lines above, which might be responsible for their anti-inflammatory potential. Structural complexity and diversity, however, is not the only reason; an important additional feature is their selectivity and specificity based on their mechanisms of action.

The selectivity inhibition of Ahp-containing depsi-peptides against elastase is increased when the Abu residue is neighbor to the Ahp residue as compared to other serine proteases. The reason for this varying activity could be the different binding preferences to the specificity pocket of the enzyme ([@B26]). Previously, several reports have been published on the related Ahp-containing protease inhibitors of cyanobacterial origin, and are assumed to be enzyme-substrate mimics ([@B22]; [@B70]). This assumption leads to the conclusion that polypeptides also inhibit elastase in a competitive way using Michaelis--Menten kinetics, since the residue between Thr and Ahp units presumably defines the specificity toward specific serine proteases([@B35]; [@B70]; [@B53]). Through identification of the IFR (interface forming residues) for serine proteases *in silico* docked to different inhibitors, it was concluded that the serine proteases interfaces prefer polar residues (with some exceptions)([@B49]).

Based on the current review, cyanobacteria are an abundant source of bioactive peptides and depsipeptides since they have been identified to produce a variety of similar anti-inflammatory polypeptides ([@B57]). It is, therefore, concluded that cyanobacteria could be one of the most promising and potential targets for drug discovery and development ([@B3]). Literature reports revealed that the cyanobacterial secondary metabolites are remarkably diverse in their structural features, with modified peptide--polyketide hybrids. They are biosynthesized by either nonribosomal polypeptide synthetases (NRPS), mixed polyketide synthase--NRPS pathways ([@B56]), or ribosomally ([@B40]).

Animal biological fluids and venoms are promising for their potential, and yet remain underestimated sources for biological agents against elastases. Animal venoms will potentiate the development of natural therapeutic and diagnostic drugs for human diseases that target different proteases.

Despite the fact that during the recent past, the synthetic libraries were being considered for the development of new lead drugs, we still believe that nature will continue to be a significant inspiring source of new anti-inflammatory drugs.

It is worth mentioning that the activity of the aforementioned polypeptides is lacking *in vivo* evaluation, however, the above-mentioned *in vitro* results may lead to *in vivo* studies of these molecules. Since most of these polypeptides are complex structures, which are difficult to synthesize chemically, to study their biological properties also requires screening of natural molecules. However, this is not the case for small molecules acting as elastase inhibitors ([@B52]). Therefore, the *in vitro* elastase inhibitory studies of the natural polypeptides embodied in this document may provide a milestone for drug development and design.
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